Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation
Katayoshi T, Uehata S, Nakashima N, et al.
Key finding
12 weeks of 250 mg/day NMN in middle-aged adults raised blood NAD+ and was associated with reduced arterial stiffness (CAVI) vs. placebo. Source: Katayoshi T, Uehata S, Nakashima N, et al. Scientific Reports, 2023.
Summary
Long-duration, placebo-controlled trial of oral NMN in healthy middle-aged Japanese adults. Participants received 125 mg NMN twice daily (250 mg/day) or placebo for 12 weeks, with cardiovascular and NAD+-metabolome endpoints measured at baseline and end of treatment. NMN supplementation significantly elevated whole-blood NAD+ and related metabolites (NMN, NAM, MeNAM) relative to placebo. A secondary analysis showed reduction in cardio-ankle vascular index (CAVI) — a measure of arterial stiffness — in the NMN group compared with placebo, with effect magnitude correlating with baseline CAVI. Safety was good; no serious adverse events and no clinically significant changes in liver or kidney function panels. The study is one of the few human NMN trials published in a peer-reviewed journal, extends prior short-term PK studies, and provides early signal for vascular-aging endpoints that will inform larger cardiovascular-focused trials. Cohort size and single-country sample limit generalizability.
For background on the compound studied here, see our NMN precursor reference.
Frequently asked questions
- What did Katayoshi et al. (2023) find about NMN?
- 12 weeks of 250 mg/day NMN in middle-aged adults raised blood NAD+ and was associated with reduced arterial stiffness (CAVI) vs. placebo. Source: Katayoshi T, Uehata S, Nakashima N, et al. "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation." Scientific Reports, 2023.
- What kind of study is Katayoshi 2023?
- It is a clinical trial on NMN published in Scientific Reports in 2023. Long-duration, placebo-controlled trial of oral NMN in healthy middle-aged Japanese adults. Participants received 125 mg NMN twice daily (250 mg/day) or placebo for 12 weeks, with cardiovascular and NAD+-metabolome endpoints measured at baseline and end of treatment. NMN supplementation significantly elevated whole-blood NAD+ and related metabolites (NMN, NAM, MeNAM) relative to placebo. A secondary analysis showed reduction in cardio-ankle vascular index (CAVI) — a measure of arterial stiffness — in the NMN group compared with placebo, with effect magnitude correlating with baseline CAVI. Safety was good; no serious adverse events and no clinically significant changes in liver or kidney function panels. The study is one of the few human NMN trials published in a peer-reviewed journal, extends prior short-term PK studies, and provides early signal for vascular-aging endpoints that will inform larger cardiovascular-focused trials. Cohort size and single-country sample limit generalizability.
- Where can I read the full Katayoshi 2023 paper?
- The primary source is available on PubMed (PMID 36797326) and via DOI 10.1038/s41598-023-29787-3.
Access the full paper
Related research
Nature Metabolism · 2019
Slc12a8 is a nicotinamide mononucleotide transporter
Oral NMN reaches tissues intact via a dedicated intestinal transporter.
Science · 2021
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
NMN improved skeletal muscle insulin sensitivity and gene expression in postmenopausal women.
Cell · 2013
Declining NAD induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging
Short-term NMN restores aged-mouse muscle NAD+ and reverses pseudohypoxic mitochondrial dysfunction, implicating NAD+ decline as a causal aging driver.